icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Evaluation of the efficacy and tolerability of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study
 
 
  Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
 
Stefan Zeuzem,1 Stefan Bourgeois,2 Susan Greenbloom,3 Maria Buti,4 Alessio Aghemo,5 Ewa Janczewska,6 Seng Gee Lim,7 Chris Corbett,8 Wouter Willems,8 Leen Vijgen,8 Sivi Ouwerkerk-Mahadevan,8 Maria Beumont,8 Rekha Sinha,9 Ronald Kalmeijer,9 Michael Biermer8
 
1JW Goethe University, Frankfurt am Main, Germany; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Toronto Digestive Disease Associates, Inc., Vaughan, ON, Canada; 4Hospital Vall d'Hebron and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 5Humanitas University, Rozzano, Italy; 6Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland; 7National University Hospital, Singapore; 8Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium; 9Janssen Research & Development, LLC, Titusville, NJ, USA

1023171

1023172

1023173

1023174

1023175

1023176